Obesity
Red Flags — when weight is a symptom, or carries danger
| Red flag | Why it matters | Action |
|---|---|---|
| Secondary endocrine cause — Cushing's, hypothyroidism, hypothalamic | Treatable underlying disease; missing Cushing's (striae, proximal myopathy, hypertension, diabetes) has serious consequences. | Targeted investigation (TFTs, overnight dexamethasone/cortisol); endocrinology if positive |
| Obstructive sleep apnoea | Untreated OSA causes daytime sleepiness (occupational risk — Daniel drives), hypertension, cardiovascular disease and accidents. | Epworth score; sleep study referral; DVLA advice if sleepiness affects driving |
| Disordered eating / eating disorder | A weight-loss-only approach can entrench or worsen an eating disorder; binge eating disorder needs specific treatment. | Assess; psychological/eating-disorder support alongside weight care; no unsupervised restrictive dieting |
| Severe complications — uncontrolled diabetes, severe OSA, decompensated comorbidity | May need urgent treatment and specialist (Tier 3/4) input. | Treat complications; specialist weight-management/relevant team |
| Mental health crisis / very low mood | Depression compounds obesity and impairs engagement; risk must be assessed. | Assess mood/risk; treat depression; support |
| Child with rapid weight gain / safeguarding concern | Severe childhood obesity may reflect a syndrome or, occasionally, neglect; needs centile-based assessment and sometimes safeguarding. | BMI centiles; family approach; specialist referral; safeguarding if indicated |
🚫 Undoing "eat less, move more"
Acknowledge the simplistic advice he's had and explain the biology of weight regain — appetite hormones defend a higher set-point.
"You've been told to eat less and move more, and it hasn't held — that's not because you failed, it's because your body actively defends its weight. That's exactly why this is a medical condition and why we sometimes need medical tools."💉 The injection conversation
Be honest: GLP-1-based drugs are effective but criteria-based (NICE TA875/TA1026 and the NHS phased rollout), adjuncts to lifestyle, with stopping rules and regain on stopping.
"The injections can genuinely help and I'm glad you asked. They work best alongside changes, the NHS offers them to people who meet certain criteria — some through specialist services and, increasingly, through GP practices — and the weight tends to come back if you stop, so we'd plan it properly, not as a quick fix."🎯 Realistic goals
A 5–10% loss meaningfully improves health; reframe success away from an idealised number.
"We don't need a dramatic number. Losing even 5–10% would noticeably improve your blood pressure, your sleep and your energy — and that's a realistic, lasting target to aim for together."🧠 Mood & the cycle
Low mood and weight feed each other; treating mood supports the weight work.
"You mentioned feeling low — that often goes hand in hand with this and can make changes harder. Let's look after your mood too, because it'll help everything else."- Lecturing / "eat less, move more"; stigmatising language
- Not screening comorbidities (T2DM, OSA, cardiovascular risk) or secondary causes
- Either refusing the GLP-1 request flatly or promising it uncritically
- Missing low mood / disordered eating
Address now
Comorbidity / risk- Uncontrolled/symptomatic diabetes or cardiovascular diseaseTreat per pathway; don't wait for weight loss
- Severe OSA with sleepinessSleep referral; DVLA advice if driving impaired
- Mental-health crisis / eating disorderMental-health / eating-disorder service
Tier 3 / 4
By BMI & comorbidity- Tier 3 specialist weight managementComplex/severe obesity; pharmacotherapy; pre-surgery
- Bariatric (Tier 4)BMI ≥40, or ≥35 with comorbidity; specialist assessment (Tier 3 not a prerequisite)
- Secondary causeEndocrinology if Cushing's/other
Tier 1–2
Primary care & community- Lifestyle / behavioural supportDiet, activity, sleep, agreed goals
- Community weight-management programmeTier 2 referral
- Comorbidity screening & monitoringHbA1c, lipids, BP, LFTs
- Ignoring urgent comorbidity while focusing only on weight
- Not matching the tier to BMI/comorbidity
- Not measuring waist / using ethnicity-adjusted thresholds
- Missing signs of a secondary cause or comorbidity
- No comorbidity screen / cardiovascular risk assessment
- Not screening OSA in a sleepy snorer who drives
- Over-investigating for rare causes with no indication
🚩 The formulation, not just the BMI
Obesity management fails when it is reduced to a single number and a single instruction. The useful "diagnosis" names the severity, the complications to treat, any reversible contributor, the drivers, and the patient's readiness — which together select the tier (lifestyle → community → specialist → surgery) and the modality. For Daniel: class 2 obesity with central adiposity, likely OSA, raised cardiovascular risk and low mood — a man who needs comorbidity treatment, a structured programme, a realistic goal, an honest conversation about GLP-1 eligibility, and his mood addressed.
- Reducing it to BMI alone with no complication/driver formulation
- Missing disordered eating that changes the approach
- Promising GLP-1/surgery without the criteria/pathway
- Not referring suspected OSA in a driver
Validate — name the request
Daniel has done his research and is braced for a refusal and a lecture. Naming the request out loud, and saying it is a reasonable thing to ask about, removes the fight before it starts. GLP-1-based medicines are an effective treatment for obesity recommended in NICE TA875 (semaglutide) and TA1026 (tirzepatide), and treating his question as sensible is simply accurate.
"You've come in about the weight-loss injections, and I think that's a completely reasonable thing to ask about — they are a genuine medical treatment for a medical condition. Let's look at whether and how they could fit for you."Explain — the real NHS route, honestly
There are two NHS routes. Semaglutide (NICE TA875) is available through specialist weight-management services for BMI ≥35 with at least one weight-related condition, for up to 2 years. Tirzepatide (NICE TA1026) is being rolled out in phases through primary care, starting with people who have the highest BMI and the most qualifying conditions (type 2 diabetes, treated hypertension, dyslipidaemia, confirmed OSA, established cardiovascular disease). Daniel does not yet have a confirmed diagnosis of any of them — which is exactly why his screen matters.
"At the moment the NHS gives these injections to people whose weight is already causing specific health problems — like high blood pressure, sleep apnoea or diabetes. You might have some of those that nobody has diagnosed yet. So the first step towards the injections is the same as the first step towards being healthier: let's find out."Negotiate — something concrete today
He must leave with action, not a promise: bloods (HbA1c, lipids, LFTs, U&E), home or ambulatory BP to confirm or exclude hypertension, an Epworth score and sleep referral, a mood check, referral to a structured weight programme, and a plan to refer to the specialist service or the practice's tirzepatide pathway as soon as he meets criteria. And a clear, non-shaming conversation about why buying online is riskier than it looks.
"Here's what I can do today: bloods, a blood-pressure check at home, a sleep assessment and a referral to a proper weight programme. When the results are back we'll know which route you qualify for — and I'll refer you the same day if you do. Please don't buy them online in the meantime; I'd rather we do this safely together."Goals are about health and function — sleep, energy, BP, the job — not a target dress or trouser size. Record them in his words and revisit them at every review.
Weight loss follows a sustained energy deficit, but the body defends its weight — appetite hormones rise and energy expenditure falls as weight comes off. That is why modest, sustainable changes beat crash diets that trigger rebound hunger and the familiar cycle of loss and regain.
Start with the biggest wins: swap energy drinks and sugary drinks for water or zero-sugar options (often several hundred kcal a day on their own); plan food for the van (a cool bag, pre-made lunches) rather than relying on garage food; regular meals rather than one large evening meal. No food is banned.
Multicomponent programmes — diet, activity and behaviour change (self-monitoring, goal-setting, relapse planning) — deliver more loss than advice alone and give the regular contact that keeps people engaged.
Local Tier 2 or commercial-partner programme. The NHS Digital Weight Management Programme (12 weeks, app-based — fits shift work) takes GP referrals for adults with BMI ≥30 (≥27.5 for people from Black, Asian and minority ethnic backgrounds) and diagnosed diabetes or hypertension — so confirming his BP opens this door too. HbA1c 42–47 → NHS Diabetes Prevention Programme.
Activity improves insulin sensitivity, BP, mood and sleep independently of weight, and is one of the strongest predictors of keeping weight off. On its own it takes off less weight than people expect — say so honestly to prevent disillusionment.
UK Chief Medical Officers' guidelines (2019): 150 minutes a week of moderate activity plus muscle-strengthening on 2 days. For a driver: a 10-minute brisk walk at each break, parking further from drops, stairs, and breaking up long sitting. Start from where he is — any increase counts.
Short or fragmented sleep raises hunger hormones and cravings and saps energy for activity. OSA and obesity feed each other: in a cohort study, 10% weight gain predicted about a 32% rise in apnoea–hypopnoea index and 10% loss about a 26% fall (Peppard, JAMA 2000).
Assess with the Epworth Sleepiness Scale and STOP-Bang, and refer to the sleep service if OSA is suspected (NICE NG202). If CPAP is needed, better sleep often makes every other change easier. Driving advice meanwhile — see 7G.
Depression and obesity are bidirectional: low mood drives comfort eating and inactivity, and weight stigma worsens mood. Untreated depression is one of the commonest reasons weight plans fail.
PHQ-9 and a risk question. Self-referral to NHS Talking Therapies. If binge-eating disorder emerges, NICE NG69 recommends a binge-eating-focused guided self-help programme first — and that treatment is not aimed at weight loss. If an antidepressant is needed, weigh the weight effects of mirtazapine and tricyclics.
Alcohol adds energy with no fullness, disinhibits eating, disrupts sleep, raises BP and compounds fatty liver disease alongside obesity.
AUDIT-C to quantify "moderate". UK Chief Medical Officers' low-risk guidance: no more than 14 units a week, spread over 3 or more days, with drink-free days. Brief intervention if above this. Cutting a few pints a week can be one of the easiest calorie wins.
- Qualifying comorbidities for the phased cohorts: type 2 diabetes, hypertension (on treatment), dyslipidaemia, obstructive sleep apnoea (confirmed by a sleep study, treatment indicated), and established atherosclerotic cardiovascular disease (ischaemic heart disease, cerebrovascular or peripheral vascular disease, or heart failure — counts once)
- Cohort 1 (from June 2025): BMI ≥40 with ≥4 qualifying comorbidities
- Cohort 2 (from June 2026): BMI 35–39.9 with ≥4 qualifying comorbidities
- Cohort 3 (planned for 2027 — check the local start date): BMI ≥40 with 3 qualifying comorbidities
- BMI thresholds are 2.5 kg/m² lower for people from the higher-risk ethnic groups; prescribing comes with behavioural "wraparound" support
- Misuse (October 2024): reminder of common GI side effects (which can cause severe dehydration and hospital admission) and of hypoglycaemia risk; be alert to misuse for weight loss outside the licensed indications, warn patients of side effects, and report suspected reactions via the Yellow Card scheme
- Aspiration under anaesthesia (January 2025): delayed gastric emptying means a potential risk of pulmonary aspiration during general anaesthesia or deep sedation — patients must tell the anaesthetist or endoscopist they take one
- Pregnancy and contraception (June 2025): not to be used in pregnancy, when trying to conceive or while breastfeeding; use effective contraception. Tirzepatide may reduce oral contraceptive effectiveness in people with overweight or obesity — use a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase. Stop tirzepatide at least 1 month before trying to conceive
- Acute pancreatitis (January 2026): warnings strengthened across the class — rare necrotising and fatal cases. Stop immediately if pancreatitis is suspected and do not restart if confirmed
- Semaglutide and NAION (February 2026): very rare risk of non-arteritic anterior ischaemic optic neuropathy — sudden visual loss needs urgent ophthalmology assessment; stop semaglutide if NAION is confirmed
- Eligibility confirmed against the relevant TA or local cohort — BMI (ethnicity-adjusted) and diagnosed comorbidities recorded
- Eating-disorder history asked directly (NICE NG69 — not a screening tool alone)
- Pregnancy excluded; contraception plan agreed (non-oral for tirzepatide initiation and dose steps)
- History of pancreatitis, gallstones, severe GI disease; diabetic retinopathy status if on glucose-lowering drugs
- On insulin or a sulfonylurea? Plan dose reductions and glucose monitoring to avoid hypoglycaemia
- Baseline weight, BMI, waist, BP, HbA1c, U&E recorded — the stopping rule needs a baseline
- Behavioural support in place; the patient understands regain on stopping
- Use BMI centiles on UK90 charts, not adult cut-offs: overweight ≥91st centile, obesity ≥98th centile
- Consider assessing comorbidities (BP, lipids, glucose, OSA, liver, psychological wellbeing) at ≥98th centile
- Family-based, multicomponent lifestyle interventions are the core; language should focus on health and the whole family, never blame the child
- Medicines and surgery for adolescents are specialist-only decisions
- Severe early-onset obesity, short stature or developmental delay → paediatric assessment for endocrine or genetic causes; consider safeguarding only where there are wider concerns about neglect, not because of weight alone
"This is a once-a-week injection that makes you feel full sooner and less hungry. We start low and go up slowly because sickness is common at first — eat smaller meals and stop when you're full. If you get severe tummy pain that goes through to your back, or you can't keep fluids down, stop it and get seen the same day. If you use the pill for contraception, you'll need condoms or a different method for 4 weeks after starting and after each dose increase. Tell any anaesthetist or endoscopy team you're on it. And the weight tends to come back if you stop, so we'll plan for the long term."
SCA: knowing that tirzepatide is now reaching primary care — but only for prioritised cohorts defined by BMI and diagnosed comorbidities — lets you give an honest "not yet, and here's how" instead of a flat no. Naming the contraception interaction is a high-value safety point.
"The specialist team will start this at a low dose and build up over a few months. Sickness usually settles. Severe ongoing tummy pain, or any sudden change in your eyesight, needs the same-day doctor. The NHS supports it for up to two years, and we'll plan together how to keep the weight off after that."
SCA: the two-year cap and the specialist-service setting are the facts most often got wrong. Pair them with the STEP-1 extension finding that about two-thirds of lost weight returns within a year of stopping.
"This is a daily injection. We'll check at three months on the full dose — if it hasn't helped enough, it isn't the right drug for you and we'll stop, which is a result in itself, not a failure."
Largely superseded in practice by the weekly agents, but TA664's short 12-week stopping rule is a useful contrast with the 6-month rules for semaglutide and tirzepatide.
"Take it with meals — if you skip a meal, or it has no fat in it, skip the capsule. It stops some of the fat in food being absorbed, so a fatty meal can mean an oily, urgent trip to the toilet; many people find it teaches them where the hidden fat is. We'll check your weight at three months to see whether it's worth carrying on."
SCA: offering orlistat as a real, available option — with the 3-month 5% rule and honest side-effect counselling — shows you can act today rather than only referring.
"Some medicines make weight gain much more likely, and this may be one of them. Please don't stop it on your own — let me talk to the team who prescribed it about whether there's an alternative that's kinder to your weight."
SCA: counselling on diet while a causative drug runs unchanged is the commonest futile version of this consultation. Naming the drug and a plan scores in Tasks.
Driving for a living — sleepiness and the DVLA
Daniel drives all day and reports afternoon sleepiness. DVLA guidance: anyone with excessive sleepiness that is, or is likely to be, affecting driving must not drive. With suspected OSA and excessive sleepiness he must not drive until the symptoms are satisfactorily controlled; with suspected or confirmed mild OSA and excessive sleepiness the DVLA must be notified if symptom control is not achieved within 3 months, and it must be notified if moderate or severe OSA with excessive sleepiness is confirmed. If his vehicle needs a Group 2 (lorry or bus) licence, standards are stricter.
This is frightening for a man whose income depends on driving — handle it as a safety conversation, arrange the sleep referral promptly, and document the advice.
"Do you ever feel sleepy while you're driving, or have you had any near-misses? I have to ask because, if the sleepiness is affecting your driving, it isn't safe to drive until it's treated. The good news is that treatment usually works quickly, and I'll get the sleep referral moving today."Stigma, shame and language
Daniel feels judged by previous appointments. Use person-first, neutral language — "weight", "BMI", "living with obesity" — not "obese", "fat" or "morbid". Ask permission before raising weight, and do not weigh or measure without explaining why. Check the practice environment too: chairs without arms, a large BP cuff, scales that go high enough, a gown that fits.
Recognise and name the blame he has absorbed: that is part of the treatment.
"I'm sorry you've felt judged before. That shouldn't happen. Weight is a medical condition with a lot of biology behind it, and I'd like us to treat it that way."Work environment and shift patterns
Long shifts, fixed delivery targets, few breaks and roadside food make "eat healthily and exercise" hard to follow. Practical adjustments — packed food, a cool bag, walking breaks — work better than generic advice. If OSA or mood affects his ability to work, a fit note with suggested adjustments may be needed.
"Tell me what a real working day looks like — when you get to eat, and where the food comes from. Let's find two or three changes that actually fit your route."Family, relationships and the food environment
Household shopping, cooking and eating patterns shape everyone's weight. Involving a partner can help — but only with the patient's agreement, and never in a way that makes food a battleground. His father's early heart attack may be a powerful, personal motivator — or a source of fatalism ("it's in my genes").
"Would it help to bring your partner next time, so we can plan meals that work for the whole household? And about your dad — family history raises your risk, but it doesn't decide it. That's why we're checking things now."Money, food insecurity and the private market
Healthy food can cost more, and time is short. Some people feel pushed to pay for private injections they cannot afford, or to buy cheaper unregulated products online. Ask about money without judgement; signpost to social prescribing or local support where it helps. If someone chooses a private prescription, they should use a registered UK pharmacy and tell their GP so records, interactions and safety advice stay joined up.
"If money's tight, let's plan around what's realistic. And if you ever do go private for the injections, please use a registered pharmacy and let us know — we want to keep you safe whichever route you take."Mood, identity and the cycle of loss and regain
Years of weight cycling leave people feeling like failures; low mood feeds comfort eating, and comfort eating feeds the shame. Framing regain as the body's biology — not a lack of character — and treating low mood directly breaks the cycle. Watch for signs of binge-eating disorder and for any thoughts of self-harm; weight stigma is associated with depression.
"Every time you've lost weight and it's come back, your body has been doing what bodies do. That isn't failure. Let's look after your mood as well, because it's part of the same picture."1–2 weeks — Results and diagnoses
HbA1c, lipids and QRISK3, LFTs (FIB-4 if raised or risk factors), U&E and TFTs if indicated. Home or ambulatory BP to confirm or exclude hypertension (NICE NG136). Epworth and STOP-Bang reviewed; sleep referral sent. PHQ-9 and any eating-disorder features. Driving advice confirmed and documented. Tier 2 / digital programme referral made. Name each new diagnosis — they are also the qualifying comorbidities for medication.
4–6 weeks — Treat the comorbidities; check engagement
Start antihypertensive or statin if indicated — do not wait for weight loss. Has he started the programme? Two or three agreed behaviour goals reviewed without judgement. Mood follow-up; Talking Therapies uptake. Check eligibility again for the specialist service or the practice's tirzepatide cohort now that diagnoses are clearer; refer if eligible. Orlistat is an option if he wants something now.
3 months — First outcome point
Weight, BMI and waist-to-height ratio. On orlistat: continue only if at least 5% lost since starting (NG246). On a GLP-1-based drug: tolerability, GI losses, hydration, contraception, mood and eating behaviour; titration progress. Sleep study result and CPAP started if needed — reassess sleepiness and driving.
6 months — Stopping-rule decision
Semaglutide: consider stopping if less than 5% of initial weight lost after 6 months (TA875). Tirzepatide: if less than 5% after 6 months on the highest tolerated dose, decide together whether to continue (TA1026). Re-check BP, HbA1c and lipids — medication doses (antihypertensives, glucose-lowering drugs) may need reducing as weight falls. Consider bariatric referral if thresholds are met.
Annually and long term — Chronic-disease review
Weight trajectory, BP, HbA1c, lipids and QRISK3, liver (FIB-4), OSA and CPAP adherence, mood. Plan for the end of a time-limited drug (semaglutide 2 years) — how to maintain. Expect and normalise regain; re-engage every time. After bariatric surgery: at least annual nutritional monitoring once discharged from the bariatric service (NICE NG246).
Memory rule — obesity monitoring framework
At every review: weight, BMI and waist-to-height (against the agreed goal, not an ideal); the comorbidity that justifies treatment (BP, HbA1c, lipids, liver, OSA); the drug's stopping rule (orlistat 3 months, GLP-1-based drugs 6 months); safety (pancreatitis and gallbladder symptoms, hydration, contraception, hypoglycaemia); and mind (mood, eating behaviour, stigma).
| What | How | When | Action threshold |
|---|---|---|---|
| Weight / BMI / waist-to-height | Same scales, light clothing; tape at the midpoint between lowest rib and iliac crest | Every review | 5–10% loss = meaningful health gain. Plateau or regain → review barriers, mood, drugs, eligibility — not blame |
| Blood pressure | Clinic; confirm with ABPM or home monitoring | Baseline, then per NG136 | Clinic ≥180/120 → assess for urgent treatment. Confirmed hypertension → treat now; review doses as weight falls |
| HbA1c | Venous | Baseline; at least annually | 42–47 non-diabetic hyperglycaemia → Diabetes Prevention Programme. ≥48 (confirmed) → type 2 diabetes pathway; expedited bariatric assessment if eligible |
| Lipids + QRISK3 | Non-fasting lipid profile | Baseline; annually | QRISK3 ≥10% → offer statin with lifestyle (NICE NG238) |
| Liver (MASLD) | LFTs; FIB-4 where indicated | Baseline; per local pathway | Raised FIB-4 → ELF test or elastography per local pathway; hepatology if advanced fibrosis likely |
| OSA | Epworth, STOP-Bang; sleep study | Baseline; after treatment | Suspected OSA with sleepiness → sleep referral and driving advice; CPAP adherence at review |
| Mood / eating | PHQ-9; direct eating-disorder questions (not SCOFF alone) | Baseline; each review | Self-harm risk → same-day assessment. Binge-eating disorder → NG69 guided self-help alongside weight care; avoid unsupervised restrictive dieting |
| GLP-1-based drug safety | Symptoms; U&E if GI losses; glucose if on insulin/sulfonylurea | Each dose step; each review | Severe persistent abdominal pain → stop, same-day assessment for pancreatitis. Persistent vomiting → U&E (AKI). Hypoglycaemia → reduce insulin/sulfonylurea |
| After bariatric surgery | FBC, ferritin, folate, B12, calcium, vitamin D, PTH, U&E, LFTs and others per BOMSS | At least annually after discharge (NICE NG246) | Deficiency → replace and review supplements; new abdominal pain after bypass → same-day surgical assessment |
⚠ Scenario-specific phrases — use these in your own words, and document them
Why safety-netting matters beyond clinical care — what to document
- Medication-only plan with no lifestyle/behavioural support or follow-up
- Idealised unrealistic targets; no comorbidity treatment
- No continuity / acknowledgement of relapse
Who you are
Daniel Price, 44, delivery driver. BMI around 38, big waist. You've lost and regained weight on countless diets and feel like a failure; previous GP appointments left you feeling judged ("eat less, move more"). You snore loudly, wake up unrefreshed and feel sleepy in the afternoons. Your blood pressure was "a bit high" last time. Your dad had type 2 diabetes and a heart attack at 55. You sit in a van all day, eat on the go (garage food, energy drinks), and your mood's been low. You've seen the weight-loss injections online and want to try them — you're hoping that's the answer.
Hidden concerns (reveal if explored)
Feeling judged (main): you're braced to be lectured. If the doctor is respectful and treats it as a medical issue, you relax and open up.
Low mood: you've been down; eating is partly comfort. You'll admit this if asked kindly.
Sleep/snoring: you'll mention it if asked; you didn't realise it could be important.
Fear it's hopeless: deep down you fear nothing will work; honest hope helps.
Clinical details if asked
- Long history of weight cycling; multiple diets; regain each time
- Snores heavily, unrefreshing sleep, daytime sleepiness (relevant — you drive for a living)
- BP "a bit high" before; strong family history (father T2DM + MI at 55)
- Sedentary job; eats on the go; sugary drinks; mood low; alcohol moderate
- No rapid recent gain; no steroid use; no cold intolerance or easy bruising
- No binge-eating "episodes" as such, but you eat to cope when stressed
Reactions at key moments
- On the respectful reframe: visibly relieved; "no one's put it like that before."
- On the injection eligibility: a bit deflated it's not instant, but accepts a clear pathway.
- On sleep apnoea: surprised but takes it seriously, especially re driving.
- On realistic goals: reassured that 5–10% is worthwhile and achievable.
- Challenge line: "So you're not just going to give me the jab? Is this another 'eat less, move more' speech?"
Resolution: Daniel engages if the GP: (1) raises weight with permission and respect, reframing obesity as a medical condition and repairing the sense of being judged; (2) assesses holistically and screens comorbidities (HbA1c, lipids, BP, OSA, cardiovascular risk) and mood, considering secondary causes; (3) is honest about the injections — effective but criteria-based, via a specialist service or the phased primary-care tirzepatide rollout, adjuncts to lifestyle, with regain on stopping — and sets him on the tiered pathway; (4) agrees realistic 5–10% goals and treats his comorbidities now; (5) arranges OSA assessment and supports his mood, with continuity. He disengages if lectured, dismissed, or promised/refused the injections without a real plan.
Classify: BMI (overweight 25–29.9; obesity I 30–34.9, II 35–39.9, III ≥40) + waist-to-height ratio if BMI <35 (≥0.5 = increased risk), ethnicity-adjusted (overweight ≥23, obesity ≥27.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds). Screen comorbidity: HbA1c, lipids, BP, LFTs (MASLD), OSA (Epworth), QRISK, mood. Secondary causes (selectively, if suggested): hypothyroid, Cushing's, PCOS; review weight-promoting drugs with the prescriber.
Tier 1–2: lifestyle/behavioural + community programmes; agree 5–10% goal. Tier 3: specialist MDT, pharmacotherapy (liraglutide/semaglutide ≤2 years; tirzepatide also via phased primary-care rollout; all with stopping rules, adjunct to lifestyle). Tier 4: bariatric surgery (BMI ≥40, or 35–39.9 with comorbidity, specialist assessment; expedited if T2DM diagnosed within 10 years; ethnicity-adjusted). Treat comorbidities now; non-stigmatising care; long-term follow-up.